KOE · 115450.KQ
HLB Therapeutics Co.,Ltd.
₩2,495-₩65 (-2.54%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.02% below the high.
Loading market information…
KSC · 011000.KS · KRW
Stock price
Quote as of Sep 5, 2026, 06:08 PM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
GeneOne Life Science, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:38 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩2,495-₩65 (-2.54%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.02% below the high.
₩5,860-₩60 (-1.01%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.05% below the high.
₩5,260-₩90 (-1.68%)
EASY BIO,Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.55% below the high.
₩13,360-₩720 (-5.11%)
Anterogen.Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 78.38% below the high.
₩10,900-₩50 (-0.46%)
Macrogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.85% below the high.
₩3,050+₩80 (+2.69%)
MedPacto, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.74% below the high.
₩2,160-₩5 (-0.23%)
Genexine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.16% below the high.
₩916+₩10 (+1.1%)
Amicogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.77% below the high.
